BackBridgeBio Pharma Overview
BridgeBio Pharma Inc

BridgeBio Pharma Target Price

Where could BBIO trade next? Consensus target price: $110.

Get informed when a big investor buys or sells

+ Follow

Share Price

$76.57

Average Target Price

$108.3841.5% upside

13 analysts in the last 4 months

High: $130 | Low: $96

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-12Truist FinancialDanielle Brill$10739.7% upsideOpen
2026-08-12Canaccord Genuity$10638.4% upsideOpen
2026-08-11Cantor FitzgeraldJosh Schimmer$11043.7% upsideOpen
2026-08-11Morgan StanleySean Laaman$9726.7% upsideOpen
2026-08-11Wells FargoDerek Archila$10233.2% upsideOpen
2026-08-11Piper Sandler$11550.2% upsideOpen
2026-07-13H.C. Wainwright$12056.7% upsideOpen
2026-06-16Mizuho SecuritiesSalim Syed$9625.4% upsideOpen
2026-06-03Canaccord Genuity$10435.8% upsideOpen
2026-05-28Morgan Stanley$9828% upsideOpen
2026-05-11H.C. Wainwright$11043.7% upsideOpen
2026-05-08Evercore ISI$13069.8% upsideOpen
2026-05-08Bernstein$11448.9% upsideOpen
2026-04-29Truist FinancialDanielle Brill$10233.2% upsideOpen
2026-04-08RBC CapitalLuca Issi$10030.6% upsideOpen
2026-03-12Leerink PartnersMani Foroohar$9828% upsideOpen
2026-02-25Truist FinancialDanielle Brill$9524.1% upsideOpen
2026-02-17H.C. WainwrightRaghuram Selvaraju$10030.6% upsideOpen
2026-02-13Tudor PickeringWilliam Pickering$10030.6% upsideOpen
2026-02-13OppenheimerTrevor Allred$838.4% upsideOpen
2026-02-12JefferiesAndrew Tsai$10030.6% upsideOpen
2026-02-12Raymond JamesMartin Auster$8916.2% upsideOpen
2026-01-27Barclays$157105% upsideOpen
2026-01-20Wells FargoTiago Fauth$8814.9% upsideOpen
2026-01-08Truist Financial$8612.3% upsideOpen
2026-01-06Morgan Stanley$9625.4% upsideOpen
2025-12-15Leerink Partners$8612.3% upsideOpen
2025-12-11Bernstein$9422.8% upsideOpen
2025-10-30Truist Financial$804.5% upsideOpen
2025-10-30Oppenheimer$815.8% upsideOpen
2025-10-30Piper Sandler$9828% upsideOpen
2025-10-30Goldman SachsPaul Choi$10030.6% upsideOpen
2025-10-29H.C. Wainwright$9017.5% upsideOpen
2025-10-28H.C. Wainwright$804.5% upsideOpen
2025-10-27Raymond James$699.9% downsideOpen
2025-10-27Leerink PartnersMani Foroohar$6811.2% downsideOpen
2025-08-29H.C. WainwrightRaghuram Selvaraju$708.6% downsideOpen
2025-04-30UBSEliana Merle$726% downsideOpen
2024-10-24CitigroupDavid Lebowitz$4541.2% downsideOpen
2024-10-17Leerink PartnersMani Foroohar$4639.9% downsideOpen
2024-09-11Piper SandlerBiren Amin$4639.9% downsideOpen
2024-09-03Mizuho SecuritiesSalim Syed$5330.8% downsideOpen
2024-06-24Raymond JamesDanielle Brill$4639.9% downsideOpen
2024-06-05BMO CapitalKostas Biliouris$3751.7% downsideOpen
2024-06-05Wells FargoTiago Fauth$5824.3% downsideOpen
2024-05-30Goldman SachsPaul Choi$5034.7% downsideOpen
2024-05-28UBSEliana Merle$4738.6% downsideOpen
2024-05-20H.C. WainwrightRaghuram Selvaraju$4343.8% downsideOpen
2024-05-13Evercore ISICory Kasimov$5034.7% downsideOpen
2022-11-18J.P. Morgan$1975.2% downsideOpen

BridgeBio Pharma (BBIO) FAQ

BridgeBio Pharma posts a target price of $110. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $110 for BBIO means covering analysts, on average, see the stock 41.5% upside of $76.57 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for BBIO's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; BridgeBio Pharma's other metric pages and overview cover the third.

Judging BridgeBio Pharma against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $110 here, then scan peer and history charts to see if the gap is persistent.